妙佑医疗国际的方法

妙佑医疗国际针对双特异性抗体疗法和细胞疗法设有一套独特的无缝衔接式门诊加住院护理。这种设置方便患者根据其当前需求获得适当的护理。妙佑医疗专业团队的医生和医务人员在照护接受这类疗法的患者方面经验丰富。妙佑医疗国际在双特异性抗体疗法的创新给药方式(例如快速阶梯式递增给药)方面处于领先地位。

获得最新疗法

妙佑医疗国际的医生掌握获批用于癌症患者的最新生物治疗方法,包括双特异性抗体疗法和 CAR T 细胞疗法。您的癌症治疗计划会将最新的信息考虑在内。

研究人员还积极参与临床试验,探索不同的双特异性抗体联合治疗方法在癌症和其他疾病(例如血友病)中的应用。这些调查研究为受试者提供了更早获得新疗法的机会,并且可能成为其他治疗方案无效的患者的首选。

专长与排名

妙佑医疗国际的医生凭借在复杂和严重疾病生物疗法领域的丰富经验而享誉全美。妙佑医疗国际综合癌症中心凭借在癌症护理领域的卓越科学成就和团队协作方式而获得美国国家癌症研究所的认可。

妙佑医疗国际明尼苏达州罗切斯特院区、妙佑医疗国际佛罗里达州杰克逊维尔院区和妙佑医疗国际亚利桑那州凤凰城/斯科茨代尔院区均在《美国新闻与世界报道》癌症治疗“最佳医院”排名中名列前茅。

位置、旅行和住宿

Mayo Clinic 在亚利桑那州的芬尼克斯和斯克茨戴尔、佛罗里达州的杰克逊威尔和明尼苏达州的罗切斯特都有主要校区。Mayo Clinic 健康系统在几个州拥有十几个工作地点。

有关参观 Mayo Clinic 的更多信息,请在下面选择您的位置:

费用与保险

妙佑医疗国际与数百家保险公司合作,是数百万人的网络内医疗服务提供者。

在大多数情况下,妙佑医疗国际不需要医生转诊。某些保险公司要求转诊,或有其他特定医疗要求。所有约诊的优先级都以医疗需求为基础。

详细了解在妙佑医疗国际约诊的信息。

请联系您的保险公司,核实承保范围,并在就医之前获得任何所需的授权。保险公司的客户服务号码通常印在保险卡背面。

March 24, 2026
  1. Klein C, et al. The present and future of bispecific antibodies for cancer therapy. Nature Reviews Drug Discovery. 2024; doi:10.1038/s41573-024-00896-6.
  2. Manis JP. Overview of therapeutic monoclonal antibodies. https://www.uptodate.com/contents/search. Accessed Sept. 30, 2025.
  3. Guidi L, et al. Bispecific antibodies in hematologic and solid tumors: Current landscape and therapeutic advances. American Society of Clinical Oncology Educational Book. 2025; doi:10.1200/EDBK-25-473148.
  4. Gu Y, et al. Clinical progresses and challenges of bispecific antibodies for the treatment of solid tumors. Molecular Diagnosis & Therapy. 2024; doi:10.1007/s40291-024-00734-w.
  5. Verma V, et al. Bispecific antibodies in clinical practice: Understanding recent advances and current place in cancer treatment landscape. Clinical and Experimental Medicine. 2025; doi:10.1007/s10238-024-01520-y.
  6. Jain MD, et al. Easy as ABC: Managing toxicities of antibody-drug conjugates, bispecific antibodies, and CAR T-cell therapies. ASCO Educational Book. 2025; doi:10.1200/EDBK-25-473916.
  7. Tan CR, et al. Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM): An International Myeloma Working Group study. Blood Cancer Journal. 2025; doi:10.1038/s41408-025-01259-z.
  8. Choi SM, et al. Mechanism of action and pharmacokinetics of approved bispecific antibodies. Biomolecules & Therapeutics. 2024; doi:10.4062/biomolther.2024.146.
  9. Medical review (expert opinion). Mayo Clinic. Sept. 30, 2025.
  10. Tecvayli (prescribing information). Janssen Biotech; 2022 https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/TECVAYLI-pi.pdf. Accessed Sept. 29, 2025.
  11. Imdelltra (prescribing information). Amgen; 2024. https://www.pi.amgen.com/-/media/Project/Amgen/Repository/pi-amgen-com/Imdelltra/imdelltra_fpi.pdf. Accessed Oct. 1, 2025.
  12. Raje N, et al. Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: Consensus recommendations from an expert panel. Blood Cancer Journal. 2023; doi:10.1038/s41408-023-00879-7.
  13. Britto J, et al. Bispecific antibody toxicities. CMAJ. 2025; doi:10.1503/cmaj.241384.
  14. Morris EC, et al. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nature Reviews Immunology. 2022; doi:10.1038/s41577-021-00547-6.
  15. Derman B, et al. Real-world evidence evaluating teclistamab in patients with relapsed/refractory multiple myeloma: A systematic literature review. Cancers. 2025; doi:10.3390/cancers17071235.
  16. Health Education & Content Services. Staying connected with remote patient monitoring. Mayo Clinic; 2022.
  17. Altered immunocompetence. Centers for Disease Control and Prevention. https://www.cdc.gov/vaccines/hcp/imz-best-practices/altered-immunocompetence.html. Accessed Nov. 14, 2025.
  18. Rybrevant (prescribing information). Janssen Biotech; 2021. https://www.accessdata.fda.gov/scripts/cder/daf. Accessed Nov. 17, 2025.
  19. Blincyto (prescribing information). Amgen; 2014. https://www.accessdata.fda.gov/scripts/cder/daf. Accessed Nov. 17, 2025.
  20. Elrexfio (prescribing information). Pfizer; 2023. https://www.accessdata.fda.gov/scripts/cder/daf. Accessed Nov. 17, 2025.
  21. Hemlibra (prescribing information). Genentech; 2017. https://www.accessdata.fda.gov/scripts/cder/daf. Accessed Nov. 17, 2025.
  22. Epkinly (prescribing information). Genmab US; 2023. https://www.accessdata.fda.gov/scripts/cder/daf. Accessed Nov. 17, 2025.
  23. Vabysmo (prescribing information). Genentech; 2023. https://www.accessdata.fda.gov/scripts/cder/daf. Accessed Nov. 17, 2025.
  24. Lunsumio (prescribing information). Genentech; 2022. https://www.accessdata.fda.gov/scripts/cder/daf. Accessed Nov. 17, 2025.
  25. Kimmtrak (prescribing information). Immunocore; 2022. https://www.accessdata.fda.gov/scripts/cder/daf. Accessed Nov. 17, 2025.
  26. Haydu E, et al. The rules of T-cell engagement: Current state of CAR T cells and bispecific antibodies in B-cell lymphomas. Blood Advances. 2024; doi.org/10.1182/bloodadvances.2021004535.
  27. Columvi (prescribing information). Genentech; 2023. https://www.accessdata.fda.gov/scripts/cder/daf. Accessed Nov. 20, 2025.
  28. Talvey (prescribing information). Janssen Biotech; 2023. https://www.accessdata.fda.gov/scripts/cder/daf. Accessed Nov. 26, 2025.